tbuckley/cabot-search huggingface dataset:
Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations
Authors: Z. Kuzbari, C. Bandlamudi, C. Loveday, A. Garrett, M. Mehine, A. George, H. Hanson, K. Snape, A. Kulkarni, S. Allen, S. Jezdic, R. Ferrandino, C.B. Westphalen, E. Castro, J. Rodon, J. Mateo, G.J. Burghel, M.F. Berger, D. Mandelker, C. Turnbull
Journal: Annals of Oncology (2022)

The European Society for Medical Oncology Precision Medicine Working Group (ESMO PMWG) was reconvened to update its 2018/19 recommendations on follow-up of putative germline variants detected on tumour-only sequencing, which were based on an analysis of 17 152 cancers.
Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial
Authors: John H Krystal, John M Kane, Christoph U Correll, David P Walling, Matthew Leoni, Sridhar Duvvuri, Shrinal Patel, Ih Chang, Philip Iredale, Lillian Frohlich, Stacey Versavel, Pamela Perry, Raymond Sanchez, John Renger
Journal: The Lancet (2022)
Pathophysiology, Echocardiographic Diagnosis, and Treatment of Atrial Functional Mitral Regurgitation
Authors: Serdar Farhan, Jeffrey J. Silbiger, Jonathan L. Halperin, Lily Zhang, Srinivas R. Dukkipati, Birgit Vogel, Annapoorna Kini, Samin Sharma, Stamatios Lerakis
Journal: Journal of the American College of Cardiology (2022)
Research Progress of Shape Memory Polymer and 4D Printing in Biomedical Application
Authors: Wei Zhao, Chengbin Yue, Liwu Liu, Yanju Liu, Jinsong Leng
Journal: Advanced Healthcare Materials (2022)

Abstract As a kind of smart material, shape memory polymer (SMP) shows great application potential in the biomedical field. Compared with traditional metal‐based medical devices, SMP‐based devices have the following characteristics: 1) The adaptive ability allows the biomedical device to better match the surrounding tissue after being implanted into the body by minimally invasive implantation; 2) it has better biocompatibility and adjustable biodegradability; 3) mechanical properties can be regulated in a large range to better match with the surrounding tissue. 4D printing technology is a comprehensive technology based on smart materials and 3D printing, which has great application value in the biomedical field. 4D printing technology breaks through the technical bottleneck of personalized customization and provides a new opportunity for the further development of the biomedical field. This paper summarizes the application of SMP and 4D printing technology in the field of bone tissue scaffolds, tracheal scaffolds, and drug release, etc. Moreover, this paper analyzes the existing problems and prospects, hoping to provide a preliminary discussion and useful reference for the application of SMP in biomedical engineering.
Unmet needs for patients with seborrheic dermatitis
Authors: J. Mark Jackson, Andrew Alexis, Matthew Zirwas, Susan Taylor
Journal: Journal of the American Academy of Dermatology (2022)

Seborrheic dermatitis (SD) is a common skin disease with signs and symptoms that may vary by skin color, associated medical conditions, environmental factors, and vehicle preference. Diagnosis of SD is based on presence of flaky, "greasy" patches, and/or thin plaques accompanied by erythema of the scalp, face, ears, chest, and groin and is associated with pruritus in many patients. The presentation may vary in different skin types and hyper- or hypopigmentation may occur, with or without erythema and minimal or no scaling. While the pathogenesis is not certain, 3 key factors generally agreed upon include lipid secretion by sebaceous glands, Malassezia spp. colonization, and some form of immunologic dysregulation that predisposes the patient to SD. Treatment involves reducing proliferation of, and inflammatory response to, Malassezia spp. Topical therapies, including antifungal agents and low potency corticosteroids, are the mainstay of treatment but may be limited by efficacy and side effects. Few novel treatments for SD are currently being studied; however, clinical trials assessing the use of topical phosphodiesterase-4 inhibitors have been completed. Improving outcomes in SD requires recognizing patient-specific manifestations/locations of the disease, including increased awareness of how it affects people of all skin types.
Standardizing Care in Pediatric Continuous Kidney Replacement Therapy—Can We Reach Consensus Without Adequate Evidence?
Authors: Katja M. Gist, Dana Y. Fuhrman, Ayse Akcan-Arikan
Journal: JAMA Network Open (2022)

Marco Daverio, MD, PhD; Gerard Cortina, MD; Andrew Jones, MBBS; Zaccaria Ricci, MD; Demet Demirkol, MD; Paulien Raymakers-Janssen, MSc; Francois Lion, MD; Cristina Camilo, MD; Vesna Stojanovic, MD, PhD; Serge Grazioli, MD; Tomas Zaoral, PhD; Katja Masjosthusmann, MD; Inge Vankessel, RN; Akash Deep, MD; Critical Care Nephrology Section of the European Society of Paediatric and Neonatal Intensive Care; Sue Taylor; Emma Alexander ; Kate Peace; Angela Amigoni; Felix Neunhoeffer
Association of Mental Health Services Access and Reincarceration Among Adults Released From Prison in British Columbia, Canada
Authors: Heather Palis, Kevin Hu, William Rioux, Mo Korchinski, Pam Young, Leigh Greiner, Tonia Nicholls, Amanda Slaunwhite
Journal: JAMA Network Open (2022)

Diagnosis of mental disorder is prevalent among people who have been incarcerated. Nevertheless, community mental health services are often limited following release from prison, and reincarceration rates are high. The prevalence of mental disorders is growing among people who are incarcerated in British Columbia (BC), Canada, increasing the urgency of timely and accessible mental health services after release.To examine the association of mental health services access and timeliness of services access with reincarceration risk among people released from prison.In this cohort study, mental disorder diagnoses were derived from International Classification of Diseases, Ninth Revision or International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes in administrative health records. Data on prison release and reincarceration were retrieved from corrections records. Population-based health and corrections data were retrieved from the BC Provincial Overdose Cohort, which contains a 20% general population random sample of 1 089 677 BC residents. This study examined releases from provincial prisons between January 1, 2015, and December 31, 2018, among people in the 20% random sample who had a mental disorder diagnosis in the year before their release. Analyses were performed from January to June 2022.Mental health services access (primary care, emergency department visits, or hospitalization) and sociodemographic, health, and incarceration characteristics.A multistate modeling approach was taken. Cox proportional hazards models were stratified by transition, from release to reincarceration, with and without mental health services access. A state arrival extended model examined the influence of timeliness of mental health services access on subsequent hazard of reincarceration.A total of 4171 releases among 1664 people (3565 releases among male individuals [84.6%]; 2948 releases [70.7%] among people <40 years old; 2939 releases [70.5%] among people with concurrent substance use disorder diagnosis) were identified. The total study follow-up time was 2834.53 person-years, with a mean (SD) of 0.68 (0.93) years and median (IQR) of 0.25 (0.07-0.84) years per release. Mental health services access was associated with a reduction in the hazard of reincarceration (hazard ratio, 0.61; 95% CI, 0.39-0.94). For each additional month between release and mental health services access, the hazard of reincarceration was increased by 4% (hazard ratio, 1.04; 95% CI, 1.01-1.07).In this cohort study of people with mental disorder diagnoses released from prison in BC, mental health services access was associated with reduced reincarceration risk. These findings suggest that these services may have the greatest impact on reducing reincarceration risk when they are available in a timely manner in the days and weeks immediately following release.
Injectable bioorthogonal hydrogel (BIOGEL) accelerates tissue regeneration in degenerated intervertebral discs
Authors: Jeffrey Luo, Anjani Darai, Thanapat Pongkulapa, Brian Conley, Letao Yang, Inbo Han, Ki-Bum Lee
Journal: Bioactive Materials (2022)

Intervertebral disc (IVD) degeneration is a leading cause of back pain and precursor to more severe conditions, including disc herniation and spinal stenosis. While traditional growth factor therapies (e.g., TGFβ) are effective at transiently reversing degenerated disc by stimulation of matrix synthesis, it is increasingly accepted that bioscaffolds are required for sustained, complete IVD regeneration. Current scaffolds (e.g., metal/polymer composites, non-mammalian biopolymers) can be improved in one or more IVD regeneration demands: biodegradability, noninvasive injection, recapitulated healthy IVD biomechanics, predictable crosslinking, and matrix repair induction. To meet these demands, tetrazine-norbornene bioorthogonal ligation was combined with gelatin to create an injectable bioorthogonal hydrogel (BIOGEL). The liquid hydrogel precursors remain free-flowing across a wide range of temperatures and crosslink into a robust hydrogel after 5-10 min, allowing a human operator to easily inject the therapeutic constructs into degenerated IVD. Moreover, BIOGEL encapsulation of TGFβ potentiated histological repair (e.g., tissue architecture and matrix synthesis) and functional recovery (e.g., high water retention by promoting the matrix synthesis and reduced pain) in an in vivo rat IVD degeneration/nucleotomy model. This BIOGEL procedure readily integrates into existing nucleotomy procedures, indicating that clinical adoption should proceed with minimal difficulty. Since bioorthogonal crosslinking is essentially non-reactive towards biomolecules, our developed material platform can be extended to other payloads and degenerative injuries.
Assessment of Care Cascades Following Low-Value Prostate-Specific Antigen Testing Among Veterans Dually Enrolled in the US Veterans Health Administration and Medicare Systems
Authors: Aimee N. Pickering, Xinhua Zhao, Florentina E. Sileanu, Elijah Z. Lovelace, Liam Rose, Aaron L. Schwartz, Allison H. Oakes, Jennifer A. Hale, Loren J. Schleiden, Walid F. Gellad, Michael J. Fine, Carolyn T. Thorpe, Thomas R. Radomski
Journal: JAMA Network Open (2022)

Older US veterans commonly receive health care outside of the US Veterans Health Administration (VHA) through Medicare, which may increase receipt of low-value care and subsequent care cascades.To characterize the frequency, cost, and source of low-value prostate-specific antigen (PSA) testing and subsequent care cascades among veterans dually enrolled in the VHA and Medicare and to determine whether receiving a PSA test through the VHA vs Medicare is associated with more downstream services.This retrospective cohort study used VHA and Medicare administrative data from fiscal years (FYs) 2017 to 2018. The study cohort consisted of male US veterans dually enrolled in the VHA and Medicare who were aged 75 years or older without a history of prostate cancer, elevated PSA, prostatectomy, radiation therapy, androgen deprivation therapy, or a urology visit. Data were analyzed from December 15, 2020, to October 20, 2022.Receipt of low-value PSA testing.Differences in the use and cost of cascade services occurring 6 months after receipt of a low-value PSA test were assessed for veterans who underwent low-value PSA testing in the VHA and Medicare compared with those who did not, adjusted for patient- and facility-level covariates.This study included 300 393 male US veterans at risk of undergoing low-value PSA testing. They had a mean (SD) age of 82.6 (5.6) years, and the majority (264 411 [88.0%]) were non-Hispanic White. Of these veterans, 36 459 (12.1%) received a low-value PSA test through the VHA, which was associated with 31.2 (95% CI, 29.2 to 33.2) additional cascade services per 100 veterans and an additional $24.5 (95% CI, $20.8 to $28.1) per veteran compared with the control group. In the same cohort, 17 981 veterans (5.9%) received a PSA test through Medicare, which was associated with 39.3 (95% CI, 37.2 to 41.3) additional cascade services per 100 veterans and an additional $35.9 (95% CI, $31.7 to $40.1) per veteran compared with the control group. When compared directly, veterans who received a PSA test through Medicare experienced 9.9 (95% CI, 9.7 to 10.1) additional cascade services per 100 veterans compared with those who underwent testing within the VHA.The findings of this cohort study suggest that US veterans dually enrolled in the VHA and Medicare commonly experienced low-value PSA testing and subsequent care cascades through both systems in FYs 2017 and 2018. Care cascades occurred more frequently through Medicare compared with the VHA. These findings suggest that low-value PSA testing has substantial downstream implications for patients and may be especially challenging to measure when care occurs in multiple health care systems.
Association Between Psychological Distress and Incident Dementia in a Population-Based Cohort in Finland
Authors: Sonja Sulkava, Jari Haukka, Raimo Sulkava, Tiina Laatikainen, Tiina Paunio
Journal: JAMA Network Open (2022)

Symptoms of psychological distress have shown association with subsequent dementia, but the nature of association remains unclear.To examine the association of psychological distress with etiological risk of dementia and incidence of dementia in presence of competing risk of death.This cohort study consisted of population-based cross-sectional National FINRISK Study surveys collected in 1972, 1977, 1982, 1987, 1992, 1997, 2002, and 2007 in Finland with register-based follow-up; and the cohort was linked to Finnish Health Register data for dementia and mortality for each participant until December 31, 2017. Participants included individuals without dementia who had complete exposure data. Data were analyzed from May 2019 to April 2022.Self-reported symptoms of psychological distress: stress (more than other people), depressive mood, exhaustion, and nervousness (often, sometimes, never).Incident all-cause dementia, ascertained through linkage to national health registers. Poisson cause-specific hazard model (emphasizing etiological risk) and Fine-Gray subdistribution hazard model (emphasizing effect on incidence) considering dementia and death without dementia as competing risks. Covariates of age, sex, baseline year, follow-up time, educational level, body mass index, smoking, diabetes, systolic blood pressure, cholesterol, and physical activity. Sensitivity analysis was performed to reduce reverse causation bias by excluding individuals with follow-up less than 10 years.Among 67 688 participants (34 968 [51.7%] women; age range, 25 to 74 years; mean [SD] age, 45.4 years), 7935 received a diagnosis of dementia over a mean follow-up of 25.4 years (range, 10 to 45 years). Psychological distress was significantly associated with all-cause dementia in a multivariable Poisson model, with incidence rate ratios from 1.17 (95% CI, 1.08-1.26) for exhaustion to 1.24 (95% CI, 1.11-1.38) for stress, and remained significant in sensitivity analyses. A Fine-Gray model showed significant associations (with hazard ratios from 1.08 [95% CI, 1.01-1.17] for exhaustion to 1.12 [95% CI, 1.00-1.25] for stress) for symptoms other than depressive mood (hazard ratio, 1.08 [95% CI, 0.98-1.20]). All the symptoms showed significant associations with competing risk of death in both models.In this cohort study, psychological distress symptoms were significantly associated with increased risk of all-cause dementia in the model emphasizing etiological risk. Associations with real incidence of dementia were diminished by the competing risk of death.
VP7-2022: An ad-hoc interim overall survival results of niraparib with individualized starting dose as maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer (NORA): A double-blind, randomized, placebo-controlled, phase III trial
Authors: M.R. Mirza, X. Wu, J. Zhu, R. Yin, J. Yang, J. Liu, J. Wang, L. Wu, Z. Liu, Y. Gao, D. Wang, G. Lou, H. Yang, Q. Zhou, B. Kong, Y. Huang, L. Chen, X. Zhen, J. Dong, J. Hou
Journal: Annals of Oncology (2022)
IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer
Authors: Olga S. Blomberg, Lorenzo Spagnuolo, Hannah Garner, Leonie Voorwerk, Olga I. Isaeva, Ewald van Dyk, Noor Bakker, Myriam Chalabi, Chris Klaver, Maxime Duijst, Kelly Kersten, Marieke Brüggemann, Dorien Pastoors, Cheei-Sing Hau, Kim Vrijland, Elisabeth A.M. Raeven, Daphne Kaldenbach, Kevin Kos, Inna S. Afonina, Paulien Kaptein, Louisa Hoes, Willemijn S.M.E. Theelen, Paul Baas, Emile E. Voest, Rudi Beyaert, Daniela S. Thommen, Lodewyk F.A. Wessels, Karin E. de Visser, Marleen Kok
Journal: Cancer Cell (2022)
Automated deep brain stimulation programming based on electrode location: a randomised, crossover trial using a data-driven algorithm
Authors: Jan Roediger, Till A Dembek, Johannes Achtzehn, Johannes L Busch, Anna-Pauline Krämer, Katharina Faust, Gerd-Helge Schneider, Patricia Krause, Andreas Horn, Andrea A Kühn
Journal: The Lancet Digital Health (2022)
Comparison of three sample types for performing LDBio Aspergillus immunochromatographic technology lateral flow assay for IgG/IgM antibody detection in chronic aspergillosis
Authors: Inderpaul Singh Sehgal, Sahajal Dhooria, Kathirvel Soundappan, Shivaprakash M. Rudramurthy, Arunaloke Chakrabarti, Ritesh Agarwal
Journal: Clinical Microbiology and Infection (2022)
Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial
Authors: Chi Leung Chiang, Keith Wan Hang Chiu, Kenneth Sik Kwan Chan, Francis Ann Shing Lee, James Chun Bong Li, Catherine Wing Suet Wan, Wing Chiu Dai, Tai Chung Lam, Wenqi Chen, Natalie Sean Man Wong, Andy Lai Yin Cheung, Venus Wan Yan Lee, Vince Wing Hang Lau, Aya El Helali, Kwan Man, Feng Ming (Spring) Kong, Chung Mau Lo, Albert Chi-Yan Chan
Journal: The Lancet. Gastroenterology & hepatology (2022)
Barcelona <scp>Bio‐HF</scp> calculator version 3.0: recalibration and incorporation of sodium–glucose cotransporter 2 inhibitor treatment
Authors: Pau Codina, Josep Lupón, Isaac Subirana, Elisabet Zamora, Mar Domingo, Evelyn Santiago‐Vacas, Germán Cediel, Andrea Borrellas, Jaume Barallat, Antoni Bayes‐Genis
Journal: European Journal of Heart Failure (2022)
Engineered Sandwich‐Structured Composite Wound Dressings with Unidirectional Drainage and Anti‐Adhesion Supporting Accelerated Wound Healing
Authors: Haipeng Wang, Wu Duan, Zhongjing Ren, Xinxin Li, Wenjie Ma, Yingchun Guan, Fuqiang Liu, Li Chen, Peng Yan, Xinguo Hou
Journal: Advanced Healthcare Materials (2022)

Abstract Proper management of exudate is of great clinical value for reducing wound infection and promoting wound healing, thus various dressings have been studied to address this widespread medical challenge. Herein, a novel sandwich‐structured composite wound dressing (SCWD), integrating of a superlyophobic (SLO) polydimethylsiloxane (PDMS) layer, a superlyophilic gauze layer, and a lyophobic PDMS layer is presented, with particular unidirectional droplet drainage and stable anti‐adhesion capabilities, which realizes effective management of wound exudate and provides a favorable environment for wound healing. Thanks to the stable SLO property on the PDMS surface with hierarchical micro/nanostructures, the continuously accumulated wound exudate at the interface between dressing and wound surface is gradually deformed, eventually passing through SLO PDMS layer through milli‐scale channels and being absorbed by gauze layer. Experimental results show that the application of SCWD can significantly reduce the occurrence of wound infection, avoid the tearing of wound tissues when replacing dressings, and accelerate wound healing by ≈20%. The combination of SCWD and lyophilized powders of stem cells supernatant (LPSCS) is verified to better accelerate the healing process. The proposed method offers great potential in clinical applications, particularly for acute trauma wound treatments.
Association of Prenatal Exposure to Benzodiazepines and Z-Hypnotics With Risk of Attention-Deficit/Hyperactivity Disorder in Childhood
Authors: Lene Maria Sundbakk, Jon Michael Gran, Mollie E. Wood, Marte Handal, Svetlana Skurtveit, Hedvig Nordeng
Journal: JAMA Network Open (2022)

Importance Evidence is limited regarding the safety of prenatal benzodiazepine and z-hypnotic exposure and its association with long-term neurodevelopment in childhood. Objective To quantify the associations of the timing and number of intervals of prenatal exposure to benzodiazepines and/or z-hypnotics with the risk of attention-deficit/hyperactivity disorder (ADHD) in childhood. Design, Setting, and Participants This cohort study used data from the 1999 to 2008 population-based Norwegian Mother, Father and Child Cohort Study, which are linked to the Medical Birth Registry of Norway, Norwegian Patient Registry, and Norwegian Prescription Database. Two populations of participants were created: a full sample and a mental health sample. The full sample included mothers and their live-born singletons, whereas the mental health sample was restricted to offspring of mothers who reported anxiety, depression, or sleeping problems during pregnancy or 6 months before pregnancy. Data were analyzed from September 2021 to February 2022. Exposures Maternal self-report of benzodiazepine and/or z-hypnotic use during pregnancy was grouped into early pregnancy exposure and middle and/or late pregnancy exposure for analysis of the association with timing of exposure, and number of 4-week intervals of exposure was classified (single [1] vs multiple [≥2]) for analysis of the association with number of exposed intervals. Main Outcome and Measures The outcome was ADHD, defined as time to ADHD diagnosis or filled prescription for ADHD medication. To control for confounding, inverse probability of treatment–weighted Cox proportional hazards regression models were used. Hazard ratios and 95% CIs were estimated. The weights were derived from propensity score modeling of the probability of benzodiazepine and/or z-hypnotic exposure as a function of potential confounders between the exposure and the outcome, including maternal symptoms of depression and anxiety. Results The full sample comprised 82 201 pregnancies, and the mental health sample included 19 585 pregnancies. In total, 681 offspring (0.8%) in the full sample and 468 offspring (2.4%) in the mental health sample were prenatally exposed to benzodiazepines and/or z-hypnotics. After weighting, exposure in early (hazard ratio, 0.74; 95% CI, 0.39-1.94) and middle and/or late (hazard ratio, 0.76; 95% CI, 0.35-1.61) pregnancy was not associated with increased risk of childhood ADHD. There was no evidence of substantial association between the number of exposed intervals during pregnancy and childhood ADHD. Conclusions and Relevance Results of this study suggest that there may be no increased risk of childhood ADHD associated with prenatal exposure to benzodiazepines and/or z-hypnotics, regardless of timing of exposure and number of exposed intervals. However, these findings should be interpreted with caution due to low study power.